infliximab (Remicade)

01/31/2010 - "In our study infliximab induction therapy was effective in most pediatric patients with therapy refractory Crohn disease."
01/01/2014 - "Colonoscopy performed after the third infliximab showed remarkable improvement in the ileocolitis. "
11/01/2013 - "The infliximab (IFX) has dramatically improved the treatment of Crohn's disease (CD). "
10/04/2009 - "Treatment with the chimeric monoclonal antibody (infliximab) is highly effective in refractory and fistulising Crohn's disease, nevertheless, infliximab resistance may occur. "
03/01/2008 - "Infliximab (IFX) therapy is highly efficacious for the induction and maintenance of remission in pediatric Crohn disease (CD). "

08/01/2013 - "Rescue therapy with infliximab (IFX) has been proven effective in a steroid-refractory attack of ulcerative colitis (UC). "
09/20/2009 - "Besides, infliximab is potent in the remission and its sustaining in ulcerative colitis. "
06/01/2007 - "Infliximab also has proven to be efficacious in patients with ulcerative colitis (UC) and has increased rates of steroid-free remission. "
06/01/2006 - "[Infliximab in active ulcerative colitis -- proven efficacy as induction and maintenance treatment]."
08/01/2001 - "Infliximab appears to be a potent agent for inducing remission in refractory patients with ulcerative colitis."

08/01/2009 - "The use of biologicals such as infliximab has dramatically improved the treatment of rheumatoid arthritis (RA). "
06/01/2009 - "Efficacy of high-throughput leukocytapheresis for rheumatoid arthritis with a reduced response to infliximab."
01/01/2002 - "Infliximab is effective in a significant number of patients with severe rheumatoid arthritis, with a good tolerability."
09/01/2003 - "A subset analysis of the Attract trial has demonstrated better efficacy of infliximab in reducing joint damage in an early rheumatoid arthritis (RA) population. "
04/01/2010 - "In rheumatoid arthritis, infliximab concentration is predictive of sustained efficacy with the same infliximab regimen and should be considered on a routine basis."

03/01/2008 - "Based on four randomized, placebo-controlled, double-blind clinical trials and nine open-label uncontrolled trials of the use of infliximab in plaque psoriasis, it was found that infliximab is a highly efficacious, rapid, sustainable, and relatively safe therapy. "
02/01/2014 - "This suggests that while the management of psoriasis patients with comorbid conditions and various unfavorable prognostic characteristics requires a multidisciplinary approach to ensure the patient obtains the best therapeutic response, infliximab is an effective and well tolerated treatment in these patients."
01/01/2009 - "Infliximab appears to be the most effective treatment for nail psoriasis to date."
06/01/2003 - "Scientists noticed the marked skin improvement of this patient and later demonstrated the efficacy of infliximab for psoriasis in a randomized, double-blind, placebo-controlled trial. "
12/01/2011 - "Infliximab is very effective in the treatment of psoriasis either with nail involvement and/or PsA. "

03/01/2002 - "In a pilot study, the anti-tumour necrosis factor alpha monoclonal antibody, infliximab, induced a rapid and significant improvement in global, peripheral, and axial disease manifestations of patients with active spondyloarthropathy. "
12/01/2012 - "Infliximab (IFX) is a monoclonal antibody against tumour necrosis factor α that is effective for treating spondyloarthritis (SpA). "
11/01/2010 - "While infliximab is efficacious, it remains to be determined whether patients who enter clinical remission with an anti-tumour necrosis factor therapy can have their treatment stopped and retain the state of remission. "
05/01/2007 - "Infliximab (IFX), an antitumor necrosis factor-alpha antibody, has demonstrated efficacy in medical management of CUC. "
10/01/2004 - "The management of perianal fistulizing disease resistant to standard treatment has greatly improved with the introduction of the anti-tumour necrosis factor-alpha antibody, infliximab. "